Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report

Abstract

A 60‐year‐old man was hospitalized because of numbness and weakness in the right upper limb. Magnetic resonance imaging revealed a large mass in the right upper lobe invading the right eighth cervical and first thoracic nerve root. Biopsy pathology confirmed primary lung adenocarcinoma with a clinical stage of cT4N0M0 IIIA, negative for anaplastic lymphoma kinase fusion gene and epidermal growth factor receptor mutations but positive for programmed death ligand 1 (3%). Neoadjuvant tislelizumab and chemotherapy were offered to this patient with Pancoast tumor, and tumor shrinkage of 71% was achieved. After the operation, surgical pathology indicated pathologic complete response (pCR). Circulating tumor cells testing was negative after the first adjuvant treatment. In this case, we provide real‐world evidence of encouraging pCR with neoadjuvant tislelizumab and chemotherapy for a patient with Pancoast tumor.

Almonertinib as a neoadjuvant therapy for patients with a superior pulmonary sulcus tumor with activated EGFR mutation: A case report

“…Compared with the efficacy of the pathologic complete response (pCR) obtained after neoadjuvant immunotherapy combined with chemotherapy reported in Tang et al (38), our patient still had viable tumor cells after neoadjuvant targeted therapy. However, the small proportion of tumor cells and the large number of inflammatory responses suggest that our neoadjuvant targeted therapy is effective.…”

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

“…This is particularly pertinent in the context of Pancoast tumors. Whilst induction chemoradiotherapy is the current standard of care based on non-randomized data [73], there is an absence of evidence beyond case reports that have explored the added role of immunotherapy in these challenging cases [74]. Further research is also urgently needed in this specific area, particularly because of the high rate of R1 resection, distant disease relapse and morbidity associated with resection.…”

Safety and efficacy of tislelizumab plus chemotherapy as preoperative treatment in potentially resectable locally advanced non-small-cell lung cancer patients

“…Tislelizumab plus chemotherapy as a preoperative therapy showed good antitumour activity in resectable oesophageal squamous cell carcinoma with high major pathological remission (MPR) rate, pathological complete remission (pCR) rate, R0 rate and acceptable toxicity [ 15–17 ]. In some case reports, specific advanced thoracic solid tumours showed MPR or even pCR after receiving tislelizumab (single agent or combined with chemotherapy), such as lung squamous cell carcinoma [ 18 ] and pancoast tumour [ 19 ]. This suggests that the preoperative use of tislelizumab in potentially resectable locally advanced NSCLC (LA-NSCLC) may provide additional benefits.…”